Full Press Release Details
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
DOYLESTOWN, PA, March 16, 2026 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
"We enter 2026 with strong momentum following a year of meaningful execution across our portfolio," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "We are particularly encouraged by the most recent data from the ongoing ACESOT trial evaluating APR-1051, including two patients achieving unconfirmed partial responses at first scan. These results provide early proof of clinical concept for APR-1051 and strengthen our conviction in the product's ability to deliver a favorable therapeutic window, supporting its potential to be a differentiated WEE1 kinase inhibitor for patients with genomically defined solid tumors who have limited treatment options. We strengthened our balance sheet with successful private placements in late 2025 and early 2026, enhancing our financial flexibility and positioning the Company to execute on key development milestones. Taken together, we believe the recent progress underscores the opportunity within our DDR portfolio and reinforces our goal of developing targeted cancer therapies that have the potential to improve outcome and quality of life for patients, while also creating value for our shareholders."
Key Business Updates and Potential Upcoming Key Milestones
ACESOT-1051: A Biomarker Focused, Phase 1 Trial of Oral WEE1 inhibitor, APR-1051
ABOYA-119: Ongoing Clinical Trial Evaluating ATR inhibitor, ATRN-119
Select Financial Results for the Fourth Quarter Ended December 31, 2025
Select Financial Results for the Year ended December 31, 2025
Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors while minimizing the effect on normal, healthy cells. Aprea's technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma. The company's lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the company website at www.aprea.com.
The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statement
Certain information contained in this press release includes "forward-looking statements", within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as "future," "predicts," "believes," "potential," "continue," "anticipates," "estimates," "expects," "plans," "intends," "targeting," "confidence," "may," "could," "might," "likely," "will," "should" or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs, and our ability to predict clinical outcomes based on such preclinical and early clinical results, our ability to continue as a going concern, and the other risks, uncertainties, and other factors described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.
| Aprea Therapeutics, Inc. | ||||||
| Consolidated Balance Sheets | ||||||
| December 31, | December 31, | |||||
| 2025 | 2024 | |||||
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 14,599,347 | $ | 22,849,885 | ||
| Prepaid expenses and other current assets | 961,899 | 726,254 | ||||
| Total current assets | 15,561,246 | 23,576,139 | ||||
| Property and equipment, net | 59,807 | 81,522 | ||||
| Restricted cash | 41,186 | 40,170 | ||||
| Other noncurrent assets | 271,162 | 281,662 | ||||
| Total assets | $ | 15,933,401 | $ | 23,979,493 | ||
| Liabilities and Stockholders' Equity | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 713,668 | $ | 1,352,240 | ||
| Accrued expenses | 2,050,690 | 2,008,735 | ||||
| Total current liabilities | 2,764,358 | 3,360,975 | ||||
| Commitments and contingencies | ||||||
| Series A convertible preferred stock, $0.001 par value, 40,000,000 shares authorized; 31,194 and 56,227 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 727,361 | 1,311,063 | ||||
| Stockholders' equity: | ||||||
| Common stock, $0.001 par value, 400,000,000 shares authorized, 8,192,538 and 5,481,055 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 8,192 | 5,481 | ||||
| Additional paid-in capital | 356,709,645 | 350,971,225 | ||||
| Accumulated other comprehensive loss | (10,634,714) | (10,627,379) | ||||
| Accumulated deficit | (333,641,441) | (321,041,872) | ||||
| Total stockholders' equity | 12,441,682 | 19,307,455 | ||||
| Total liabilities and stockholders' equity | $ | 15,933,401 | $ | 23,979,493 |
| Aprea Therapeutics, Inc. | ||||||||||||
| Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||
| (unaudited) | ||||||||||||
| Grant revenue | $ | 3,337 | $ | 205,817 | $ | 285,759 | $ | 1,502,581 | ||||
| Operating expenses: | ||||||||||||
| Research and development | 1,008,839 | 2,359,086 | 7,043,035 | 9,363,537 | ||||||||
| General and administrative | 1,637,591 | 1,072,776 | 6,476,560 | 6,458,699 | ||||||||
| Total operating expenses | 2,646,430 | 3,431,862 | 13,519,595 | 15,822,236 | ||||||||
| Loss from operations | (2,643,093) | (3,226,045) | (13,233,836) | (14,319,655) | ||||||||
| Other income (expense): | ||||||||||||
| Interest income, net | 118,664 | 274,626 | 652,086 | 1,289,144 | ||||||||
| Other income | 77,500 | - | 77,500 | - | ||||||||
| Foreign currency (loss) gain | (8,701) | 56,620 | (95,319) | 71,800 | ||||||||
| Total other income | 187,463 | 331,246 | 634,267 | 1,360,944 | ||||||||
| Net loss | $ | (2,455,630) | $ | (2,894,799) | $ | (12,599,569) | $ | (12,958,711) | ||||
| Other comprehensive (loss) income: | ||||||||||||
| Foreign currency translation | (5,180) | (22,632) | (7,335) | (16,106) | ||||||||
| Total comprehensive loss | $ | (2,460,810) | $ | (2,917,431) | $ | (12,606,904) | $ | (12,974,817) | ||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.32) | $ | (0.49) | $ | (1.93) | $ | (2.35) | ||||
| Weighted-average common shares outstanding, basic and diluted | 7,687,961 | 5,954,700 | 6,538,722 | 5,509,921 |